Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Neurocrine Biosciences

5 clinical trials · 5 recruiting · INDUSTRY

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Trials by Neurocrine Biosciences

RECRUITINGPhase 3NCT06966401

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With...

This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.

Sponsor: Neurocrine BiosciencesEnrolling: 60018 locations
Major Depressive Disorder
RECRUITINGPhase 3NCT06911112

NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants...

The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.

Sponsor: Neurocrine BiosciencesEnrolling: 20010 locations
Major Depressive Disorder
RECRUITINGPhase 4NCT07105111

A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain...

This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.

Sponsor: Neurocrine BiosciencesEnrolling: 508 locations
SchizophreniaSchizoaffective DisorderBipolar Disorder+2
RECRUITINGPhase 2NCT07288320

An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current...

The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving manic symptoms in adults with bipolar I disorder who are...

Sponsor: Neurocrine BiosciencesEnrolling: 1506 locations
Bipolar I DisorderMania
RECRUITINGPhase 3NCT07105098

NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.

Sponsor: Neurocrine BiosciencesEnrolling: 2845 locations
Schizophrenia